Detection of nucleic acids from multiple types of human papillomaviruses
AssigneeGen-Probe Incorporated
InventorsSylvia A. Norman, Jennifer J. Bungo, William L. Hanna, Neeraj P. Rao
Life of this patent
Estimating the term…
Abstract
Nucleic acid oligonucleotide sequences are disclosed which include amplification oligomers and probe oligomers which are useful for detecting multiple types of human papillomaviruses (HPV) associated with cervical cancer. Methods for detecting multiple HPV types in biological specimens by amplifying HPV nucleic acid sequences in vitro and detecting the amplified products are disclosed.
Claims24
A combination of oligonucleotides for detecting human papillomavirus (HPV) target sequences in multiple HPV types, comprising:
- amplification oligonucleotides comprising sequences consisting of SEQ ID Nos. 42, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, sequences that are completely complementary to SEQ ID Nos. 42, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, RNA equivalents of SEQ ID Nos. 42, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 40 and 41, or RNA equivalents of the sequences that are completely complementary to SEQ ID Nos. 42, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41.
A combination of oligonucleotides for detecting human papillomavirus (HPV) target sequences in multiple HPV types, comprising:
- amplification oligonucleotides comprising sequences consisting of SEQ ID Nos. 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, sequences that are completely complementary to SEQ ID Nos. 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40, and 41, RNA equivalents of SEQ ID Nos. 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40, and 41, or RNA equivalents of the sequences that are completely complementary to SEQ ID Nos. 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40, and 41.
A method of detecting the presence of human papillomavirus (HPV) nucleic acid present in a biological sample, comprising the steps of:
- contacting nucleic acid in a biological sample containing RNA of at least one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 with a combination of amplification oligonucleotides that amplify a HPV target sequence in an E6/E7 target region sequence, comprising one of the following combinations of amplification oligonucleotides:
- (1) amplification oligonucleotides comprising sequences consisting of SEQ ID Nos. 42, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, sequences that are completely complementary to SEQ ID Nos. 42, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, RNA equivalents of SEQ ID Nos. 42, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, or RNA equivalents of the sequences that are completely complementary to SEQ ID Nos. 42, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41;
- or
- (2) amplification oligonucleotides comprising sequences consisting of SEQ ID Nos. 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, sequences that are completely complementary to SEQ ID Nos. 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, RNA equivalents of SEQ ID Nos. 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41, and RNA equivalents of the sequences that are completely complementary to SEQ ID Nos. 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 38, 39, 40 and 41;
- amplifying a HPV target sequence from the target region sequence in at least one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 by using the amplification oligonucleotides and a nucleic acid polymerase in vitro to produce an HPV amplified product;
- and
- detecting the amplified product to indicate the presence in the sample of at least one of HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68 present in the biological sample.
Dependencies are inferred from the claim text.